antiviral drug-resistant mutation in a viral protein. The medication further comprises a synthetic peptide that comprises the predetermined antiviral drug-resistant mutation and at least six amino acid residues flanking that mutation that are identical to the amino acid sequence of the viral protein of the antiviral drug-resistant virus. The synthetic peptide induces a cytotoxic T lymphocyte (CTL) response specific for cells infected with the antiviral drug-resistant virus. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved. Further, the compositions and methods of this technology are useful to target many viruses that can develop antiviral drug resistance, including HIV-1, HIV-2, hepatitis B virus, hepatitis C virus, and human herpesviruses.

Design of a Novel Peptide Inhibitor of HIV Fusion That Disrupts the Internal Trimeric Coiled-coil of gp41

Marius G. Clore, Carole A. Bewley, and John M. Louis (NIDDK).


Licensing Contact: Sally Hu; 301/435–5606; e-mail: hus@mail.nih.gov.

This invention provides a peptide derived from the sequence of the N-terminal helix (residues 546–581) of the gp41 ectodomain of HIV-1. The peptide, called N36Mat(c), contains nine substitutions and disrupts interactions with the C-terminal region of the gp41 ectodomain. N36Mat(c) inhibits HIV-envelope mediated cell fusion about 50-fold more effectively than the native sequence (residues 546–581 of HIV–1 envelope) from which it was derived. Thus, N36Mat(c) and derivatives has potential as an anti-HIV therapeutic agent as a HIV fusion inhibitor.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Diabetes Complications in Animals.

Date: September 1, 2005.

Time: 11:00 a.m. to 1 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).


Dated: August 4, 2005.

Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging Bioengineering; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Biomedical Imaging and Bioengineering. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Biomedical Imaging and Bioengineering.

Date: September 14, 2005.

Open: 8 a.m. to 12:30 p.m.

Agenda: Report of the Director; Strategic Plan Development; Training and Career Development; Staff and Guest Speaker Scientific Presentations.

Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Closed: 1:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Contact Person: Anthony Demsey, PhD, Director, Office of Extramural Policy, National Institute of Biomedical Imaging and Bioengineering, 6701 Democracy Blvd, Room 241, Bethesda, MD 20892.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on the notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute’s/Center’s home page: http://www.nihbi.nih.gov/meetings/index.htm, where an agenda and any additional information for the meeting will be posted when available.

Dated: August 4, 2005.

Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institutes of Child Health and Human Development; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institutes of Child Health and Human Development Special Emphasis Panel, July 27, 2005, 1 p.m. to July 27, 2005, 1:30 p.m. National Institutes of Health, 6100 Executive Boulevard, 5th Floor Conference Room, Rockville, MD 20852 which was published in the Federal Register on July 22, 2005, 70 FR 42354. The meeting will be held August 9, 2005 at 12 p.m. to 12:30 p.m. The meeting is closed to the public.

Dated: August 4, 2005.

Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Neurological Disorders and Stroke Council.

The meeting will be open to the public as indicated below, with attendance limited to space available.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Closed: 1:30 p.m. to 4:30 p.m.

Agenda: Strategic Plan Development; Training and Career Development; Staff and Guest Speaker Scientific Presentations.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on the notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute’s/Center’s home page: http://www.nihbi.nih.gov/meetings/index.htm, where an agenda and any additional information for the meeting will be posted when available.

Dated: August 4, 2005.

Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.

BILLING CODE 4140-01-M